Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramucirumab - Eli Lilly and Company

Drug Profile

Ramucirumab - Eli Lilly and Company

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Basilea Pharmaceutica; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Head and neck cancer; Pancreatic cancer; Soft tissue sarcoma
  • No development reported Adenocarcinoma; Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (SC)
  • 02 Jun 2023 Efficacy and adverse events data from a phase II trial in non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 23 Apr 2023 Eli Lilly and Company completes the phase Ib/II RACING study in Pancreatic cancer (First-line therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in Greece (IV) (NCT03745430)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top